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Bone marrow mesenchymal stem cells (BMSCs) represent a promising tool for stem 
cell-based therapies. However, the majority of BMSC transplants only allow for 
limited recovery of the lost functions. We previously found that human cerebrospinal 
fluid (hCSF) is more potent than growth factors in differentiating human BMSCs into 
neuron-like cells in  vitro. In this study, we studied the effect of transplantation of rat 
BMSC-derived neuron-like cells (BMSC-Ns) induced by hCSF into rat brain with middle 
cerebral artery occlusion (MCAO). The survival and differentiation of the transplanted 
cells were determined using immunofluorescence staining of bromodeoxyuridine. The 
recovery of neurological function were observed by the modified neurological severity 
score (modified NSS) at 4, 15, and 32 days after cell transplantation, HE staining for 
determination of the infarct volume at day 32 after cell transplantation. Transplantation 
of BMSC-Ns or BMSCs significantly improved indexes of neurological function and 
reduced infarct size in rats previously subjected to MCAO compared with those in the 
control group. Remarkably, 32 days after transplantation, rats treated with BMSC-Ns 
presented a smaller infarct size, higher number of neuron-specific, enolase-positive, and 
BrdU-positive cells, and improved neurological function compared with BMSC group. 
Our results demonstrate that transplantation of hCSF-treated BMSC-Ns significantly 
improves neurological function and reduces infarct size in rats subjected to MCAO. This 
study may pave a new avenue for the treatment of MCAO.
Keywords: cerebrospinal fluid, bone marrow mesenchymal stem cells, BMsc-derived neural cells, middle 
cerebral artery occlusion
inTrODUcTiOn
Stroke is an important cause of death and disability in adults. However, endogenous neural stem 
cells (NSCs) in the brain with poor ability to migrate and differentiate into functional neurons only 
proliferated during a certain period after brain tissue damage (1). Bone marrow mesenchymal stem 
cells (BMSCs) present a diversity of functions. Transplantation of these cells facilitates recovery 
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in animal models of cerebral ischemia via mechanisms that may 
include replacement of damaged cells, neuroprotection, induc-
tion of axonal sprouting, and neovascularization (2–6). However, 
studies have shown that the ratio of BMSCs differentiating into 
glial cells and fibroblasts after transplantation in  vivo is higher 
than the ratio of BMSCs differentiating into neuron-like cells (7, 
8). Excessive glia and fibroblasts can increase glial scar formation 
(9). Therefore, we theorized that BMSCs in vitro differentiation 
into more neuronal precursor cells than glia and fibroblasts 
before transplantation may represent a more effective therapeutic 
strategy. We previously successfully induced the differentiation 
of BMSCs into neuron-like cells using human cerebrospinal fluid 
(hCSF) (10, 11). In the present study, human CSF-treated rat 
BMSCs were injected stereotaxically into the brain of rats with 
focal cerebral ischemia caused by middle cerebral artery occlusion 
(MCAO). The survival and differentiation of the implanted cells 
and recovery of neurological function were determined to explore 
the feasibility of using hCSF-treated BMSC-derived neuron-like 
cells (BMSC-Ns) transplantation to treat focal cerebral ischemia.
MaTerials anD MeThODs
experimental animals
Three-month-old Sprague-Dawley rats (270–300 g, n = 72) and 
1-month-old Sprague-Dawley rats (100–150  g, n  =  16) were 
provided by the Experimental Center of Xuzhou Medical College. 
Rats were housed in groups of four per standard polycarbonate 
cage in a temperature- and humidity-controlled colony room 
with 12-h/12-h light/dark cycle (lights on at 07:00 a.m.) and 
ad libitum access to food and water. All animal experiments were 
conducted and approved by the Institutional Animal Care and 
Use Committee of Xuzhou Medical College and the methods were 
carried out in accordance with approved guidelines (Assurances 
No. 2015-46, 2015-47).
separation, cultivation, and  
induction of Mscs
The BMSCs were isolated and harvested as previously described 
(12). In brief, Bone marrow cells from rats weighting 100–150 g 
were harvested and introduced into T25 flask (BD Falcon™, 
Franklin lakes, NJ, USA) and cultured in a complete medium 
containing 10% fetal bovine serum (FBS, HyClone, Logan, UT, 
USA) and assorted by fluorescence-activated cell sorting (FACS), 
as described previously (10, 11).
Bromodeoxyuridine – labeling
P3-generation of BMSCs were cultured in medium containing 
10  μmol/l bromodeoxyuridine (BrdU) solution (Sigma, St. 
Louis, MO, USA). At 80% confluent, cells were collected and 
resuspended in PBS. Approximately 2 × 103 cells were plated in a 
24-well plate. Rabbit anti-mouse BrdU antibody (1:200; Wuhan 
Boster Biological Technology, Ltd., China) was added and incu-
bated overnight at 4°C before goat anti-rabbit IgG-HRP polymer 
(Sigma, St. Louis, MO, USA) was added. Diaminobenzidine was 
added for color development, hematoxylin for re-staining, and 
hydrochloric acid in alcohol for differentiation. The cells were then 
dehydrated using a gradient of ethanol concentrations, cleared 
with xylene, and mounted with neutral gum. BrdU-labeled cells 
and total cells were counted under five non-overlapping fields.
In Vitro Differentiation of BMscs  
into neurons
P3-generation BMSCs were incubated with medium contain-
ing 20% hCSF. The CSF samples were obtained from healthy 
adult human volunteers. The medical ethics committee of the 
affiliated hospital of Xuzhou medical college approved the study 
(Assurances No. xyfylw2012034). At day 4 post-induction by 
hCSF, cells were digested with 0.25% trypsin and resuspended 
to a concentration of 1 × 107 cells/ml. Cell differentiation state 
was examined using microscopy, Western blot analysis, and fluo-
rescent immunohistochemistry staining as described previously 
(10, 11).
Development of Focal cerebral ischemia 
and neurological assessment
A rat model of focal cerebral ischemia was generated using suture-
occlusion of the middle cerebral artery as reported by Longa 
et al. (13). Briefly, the right middle cerebral artery was occluded. 
Twenty-four hours after the occlusion, the rats underwent neu-
rological scoring using the 5-level neurological severity score 
ranging from 1 to 3 points. Every effort was made to minimize 
the number of animals used and animal suffering.
Middle cerebral artery occlusion rats were randomly divided 
into three groups (n = 24 rats per group). The BMSC-N group was 
injected with 20 μl of BrdU-labeled BMSC-Ns, which had been 
induced with hCSF for 4 days; the BMSC group was injected with 
20 μl of BrdU-labeled P3-generation BMSCs; the control group 
was injected with 20 μl of artificial CSF (Sigma, St. Louis, MO, 
USA). The cells (1 × 106 cells) were injected into the lateral ven-
tricles stereotaxically 7 days after successful MCAO. Neurological 
assessment was based on a modified neurological severity score 
(modified NSS) method (14) (Table S1 in Supplementary Material) 
on day 7 after MCAO (day 0 before cell transplantation), and days 
4, 15, and 32 after cell transplantation.
cell survival and Migration after 
Transplantation
After being anesthetized with pentobarbital sodium, rats were 
perfused transcardially with saline, and the brain was removed 
and frozen immediately in liquid nitrogen. Brain was sliced at 
14 μm thickness using a LEICA 1800 cryostat microtome. The 
slices were stained alternatively for neuronal specific enolase 
(NSE, neuronal marker) or rabbit anti-rats glial fibrillary acidic 
protein (GFAP, a astrocyte marker), mouse anti-BrdU antibody 
(1:100), rabbit anti-rats NSE antibody (1:200; Wuhan Boster 
Biological Technology, Ltd., China) or rabbit anti-rats GFAP anti-
body (1:200; Wuhan Boster Biological Technology, Ltd., China) at 
37°C. After being washed with PBS, the FITC-labeled anti-mouse 
IgG and Texas Red-labeled anti-rabbit IgG (Sigma, St. Louis, MO, 
USA) were added to the tissue drop wise and then incubated 
in the dark for 60 min before incubation with 4′,6-diamidino-
2-phenylindole (DAPI; Sigma, St. Louis, MO, USA) for 5 min to 
FigUre 1 | characteristics of rat BMscs. (a–c) show BMSCs cultured for 1, 7 days and the P3-generation cells, respectively (40×). Scale bar = 100 μm.  
(D–g) show flow cytometry analysis of cell surface markers. On P3-generation cells: a approximately 95% of events were positive for CD29 (D) and CD90 (e) and 
were negative for CD54 (F) and CD45 (g).
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label cell nuclei. Five non-overlapping fields from the cerebral 
ischemia side were selected for immunofluorescence observation 
with a total of 20 fields per animal. NSE+ or GFAP+ cells were 
counted to determine the differentiation rate of BrdU cells into 
neuron or glia. The differentiation rate was calculated as (BrdU/
NSE double-labeled cells or BrdU/GFAP double-labeled cells/
total BrdU cells) × 100%.
Determination of Volume of cerebral 
infarction by he staining
Rats were given intravenous injections of 60 mg/kg pentobarbital 
sodium at day 7 after modeling and 32 days (n = 6 in each group) 
after transplantation. The brain tissues were quickly removed 
covering the infarct area and the surrounding brain tissues. The 
specimens were fixed in 4% formaldehyde and then placed in 
0.01 mol PBS buffer solution (pH = 7.4). Twelve hours later, the 
specimens were successively placed in 70% ethanol solution, 80% 
ethanol solution, 90% ethanol solution, 95% ethanol solution, 
and 100% ethanol solution in order to be dehydrated, followed 
by transparency with xylene, and then embedded in paraffin. 
The brain tissues underwent consecutive paraffin section with 
the LEICA RM2125 microtome. The thickness of each slice was 
4 μm. The slices were conventionally dewaxed with xylene and 
washed with decreasing concentrations of ethanol until only 
water was used. They were stained with hematoxylin for 5 min 
and then washed with tap water. They underwent differentia-
tion with hydrochloric acid ethanol for 30 s and then soaked in 
tap water for 15 min. They were placed in eosin for 2 min and 
then underwent conventional dehydration, transparency, and 
mounting. Six consecutive slices in the infarct zone were taken 
for photographing with a digital camera. An image processing 
software (i Motic Med 6.0 digital medical image analysis system) 
was used to measure the infarct size and to calculate the ratio of 
infarct area to the area of the injured hemisphere.
Data analyses
Data are expressed as the mean ±  SD. One-way ANOVA and 
independent samples Student’s t-test were used. The significance 
level was set at p < 0.05. All statistical tests were conducted using 
the SPSS v13 (IBM, Armonk, NY, USA) software package.
resUlTs
Morphological characterization of 
isolated, cultured, and induced BMscs
Primary cultured BMSCs appeared round and translucent with 
good refractivity and had mixed bone marrow mononuclear 
cells. A small number of adherent cells were visible 24  h after 
inoculation. These cells were spindle-shaped, similar to fibro-
blasts, grew in a colony-like manner, and gradually increased 
in number (Figure 1A). After approximately 1 week, these cells 
were arranged in a swirled pattern (Figure 1B). The growth rate 
was elevated with passage (Figure  1C). Thirty-six hours after 
induction, cell bodies appeared to be retracting, that is, the cells 
FigUre 3 | Modified neurological severity scores (Modified nss) of 
each group at day 7 after McaO, 4, 15, and 32 days after 
transplantation. Significance levels are as shown in Table 1.
FigUre 2 | characteristics of hcsF-induced rat BMsc-differentiated neuron-like cells. (a,B) show post-induction by hCSF at day 1 and 4 (40×). Scale 
bar = 100 μm. (c) The protein levels were measured by a GELDOC instrument and normalized with respect to β-actin, which was chosen as an internal control. 
Each experiment was repeated at least three times. Variations in protein expression are given as arbitrary units. The expression of NES in cells induced by hCSF 
(0.43 ± 0.07) was significantly higher than that of P3-generation BMSCs (0.09 ± 0.03); meanwhile, GFAP also had small amount of expression (0.09 ± 0.02). 
However, P3-generation of BMSCs almost did not express GFAP (0 ± 0). (D–F) show Cells were positive for both NSE and GFAP, but expression levels for NSE 
were higher than GFAP. Western blot analysis of NSE and GFAP protein expression (200×). Scale bar = 100 μm.
4
Ye et al. Cells for Treatment of MCAO
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 183
were lighter in color and many protrusions formed below the 
retracted balls (Figure 2A), which gradually tapered irregularly 
and then formed into triangles on day 4 (Figure 2B). More than 
95% of P3-generation cells were positive for CD29 and CD90 
and were negative for CD54 and CD45 (Figures 1D–G). At day 
4 post-induction by hCSF, cells were positive for both NSE and 
GFAP, but expression levels for NSE were higher than GFAP 
(Figures 2D–F). Western blot analysis of NSE and GFAP protein 
expression. The protein levels were measured by a GELDOC 
instrument and normalized with respect to β-actin, which was 
chosen as an internal control. Each experiment was repeated at 
least three times. Variations in protein expression are given as 
arbitrary units. The expression of NES in cells induced by hCSF 
(0.43 ± 0.07) was significantly higher than that of P3-generation 
BMSCs (0.09 ± 0.03), meanwhile GFAP also had small amount 
of expression (0.09 ± 0.02). However, P3-generation of BMSCs 
almost did not express GFAP (0 ± 0) (Figure 2C).
Behavioral assessment
Middle cerebral artery occlusion rats presented neurological 
deficits, for example, left limb flexion, circling, falling of the limb 
to the paralyzed side, as well as other signs. The modified NSS of 
the rats were not different among the three groups before trans-
plantation. The score of the BMSC-N group were significantly 
lower than that in the control or the BMSC group (p < 0.05). The 
modified NSS in the BMSC group were significantly lower than 
those in the control group on days 4 and 15 after transplantation 
(p < 0.05); however, the scores between these groups did not differ 
significantly on day 32 after transplantation (Figure 3; Table 1).
BrdU-Positive cell labeling  
after cell implantation
BrdU-positive cells were visualized in the BMSC-N and BMSC 
groups on day 32 after transplantation (Figure  4). These cells 
TaBle 1 | effects of BMsc-ns and BMscs transplantation on neurological performance, BrdU labeling, and cell differentiation (data represent 
mean ± sD, n = 8 per group): modified neurological severity scores with time after transplantation.
Treatment Day 7 after McaO Day 4 after transplantation Day 15 after transplantation Day 32 after transplantation
BMSC-N 14.63 ± 0.42 8.38 ± 0.32a,b,c 6.00 ± 0.32a,b,c 3.25 ± 0.25a,b,c
BMSC 14.63 ± 0.38 9.63 ± 0.32a,c 9.00 ± 0.27a,c 5.38 ± 0.32c
Control 14.38 ± 0.42 12.00 ± 0.38 11.00 ± 0.46 7.25 ± 0.96c
aSignificantly different (p < 0.05) compared with controls during the same time period.
bSignificantly different (p < 0.05) compared with the BMSC group during the same time period.
cSignificantly different (p < 0.05) compared with day 7 after MCAO.
FigUre 4 | immunofluorescent staining of brain slices on day 32 after transplantation. Cells labeled with green are BrdU-positive cells (arrows).  
(a) BMSC-N group, (B) BMSC group, and (c) the control group. Scale bar = 100 μm. Significance levels are as shown in Table 2.
TaBle 2 | effects of BMsc-ns and BMscs transplantation on 
neurological performance, BrdU labeling, and cell differentiation (data 
represent mean ± sD, n = 8 per group): comparison of the number of 
BrdU-labeled cells.
Treatment group BrdU-labeled cells 32 days after  
transplantation (N/5 fields)
BMSC-N 52.31 ± 8.03a,b
BMSC 19.31 ± 2.21a
Control 0.00 ± 0.00
Data represent mean ± SD, with n = 8 per group.
aSignificantly different compared with controls (p < 0.05).
bSignificantly different compared with the BMSC group (p < 0.05).
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were mainly located in the ischemic area and ischemic border 
zone. Only a few BrdU-positive cells were observed in the con-
tralateral hemisphere. BrdU-positive cells with green labeling 
were not observed in the control group (Figure 4C). Meanwhile, 
the density of BrdU-positive cells was significantly higher in the 
BMSC-N group than that in the BMSC group (Table 2).
BrdU/nse and BrdU/gFaP  
Double-labeling after cell Transplantation
Both BrdU/GFAP- and BrdU/NSE-positive double-labeled cells 
were visualized in brain slices from the BMSC-N and BMSC 
groups on day 32 after cell transplantation. The number of 
BrdU/GFAP-positive double-labeled cells or BrdU/NSE-positive 
double-labeled cells in the BMSC-N group was higher than that 
in the BMSC group. The BMSC-N group showed more BrdU/
NSE-positive double-labeled cells than BrdU/GFAP-positive 
double-labeled cells (Figure  5). Conversely, the BMSC group 
had more BrdU/GFAP-positive double-labeled cells than BrdU/
NSE-positive double-labeled cells (Table 3).
severity of Brain injury and Brain cell 
Morphology evaluated Using he staining
At day 7 after MCAO, it was visible that the nerve cells were sig-
nificantly reduced in size in the right frontotemporal cortex and 
basal ganglia; the neurons in the infarct area and the surrounding 
surviving neurons had shrunk and became deformed; the nucleus 
had shrunk and became deformed, fragmented, or completely 
dissolved; and the interstitial edema was significant. Under light 
microscope by HE staining, it was observed that all rats in three 
groups showed cystic necrosis in the cerebral ischemia area; a 
large number of neurons were lost; there were more small grid 
cells and few neutrophils; and the nucleus had shrunk and become 
deformed in the area surrounding the necrosis, where unobvious 
proliferation of glial cells and leukocyte infiltration appeared. The 
damage and loss of nerve cells in the BMSC-Ns group and BMSCs 
group were relatively mild. There were no hyperchromatic het-
erocysts with larger nuclei visible in the area surrounding the 
necrosis. The proliferation of glial cells in the BMSC-Ns group 
was less than that of the BMSCs group. There was no significant 
difference between various groups before transplantation; the 
infarct area in each group was reduced after transplantation com-
pared with that before transplantation (p < 0.05) (0.37 ± 0.019%) 
in the BMSC-Ns group, (0.52 ±  0.048%) in the BMSCs group, 
and (0.57 ± 0.031%) in the control group. The infarct volume was 
FigUre 6 | Mensuration of infarct volumes in various groups before 
and after transplantation by he staining. (a) The ratio of infarct area was 
0.83% after modeling, (B) the ratio of infarct area was 0.38% in the BMSC-N 
group, (c) the ratio of infarct area was 0.51% in the BMSC group, and  
(D) the ratio of infarct area was 0.57% in the control group.
TaBle 3 | effects of BMsc-ns and BMscs transplantation on 
neurological performance, BrdU labeling, and cell differentiation (data 
represent mean ± sD, n = 8 per group): comparison of the antigen 
differentiation ratios of neural cells after cell implantation.
group nse differentiation ratio gFaP differentiation ratio
BMSC-N 0.57 ± 0.05 0.4 ± 0.02a,b
BMSC 0.12 ± 0.03 0.32 ± 0.04b
Control 0.00 ± 0.00 0.00 ± 0.00
Data represent mean ± SD.
aBMSC-N and BMSC groups are significantly different (p < 0.01).
bNSE differentiation ratio and GFAP differentiation ratio are significantly different 
p < 0.01.
FigUre 5 | Distribution of transplanted cells in the ischemic core of 
the brain on day 32 after transplantation in rats subjected to McaO. 
Green labeling indicates BrdU-positive cells. DAPI (blue) labels nuclei. 
Immunofluorescent staining showing BrdU-positive transplanted cells (green) 
and NSE-positive cells (or GFAP-positive cells) (red). BrdU/NSE-positive 
double-labeled cells (or BrdU/GFAP-positive double-labeled cells) (yellow) 
(a,B) BMSC-N group; (c,D) BMSC group. The number of BrdU/GFAP-
positive double-labeled cells or BrdU/NSE-positive double-labeled cells in the 
BMSC-N group was higher than that in the BMSC group. The BMSC-N 
group showed more BrdU/NSE-positive double-labeled cells than BrdU/
GFAP-positive double-labeled cells. Conversely, the BMSC group had more 
BrdU/GFAP-positive double-labeled cells than BrdU/NSE-positive double-
labeled cells. Significance levels are as shown in Table 3. Scale 
bar = 100 μm.
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reduced in the BMSC-Ns group compared with the control group 
(p < 0.01), but was not significantly different between the BMSCs 
group and the control group (Figure 6).
DiscUssiOn
In recent years, with the development of regenerative medicine, 
stem cell transplantation for the treatment of central nervous 
system disease is considered to be a way of great potential. 
MSCs are considered as one of the most useful types of stem 
cells (15). However, studies have shown that the ratio of BMSCs 
differentiating into glial cells and fibroblasts after transplanta-
tion in  vivo is higher than the ratio of BMSCs differentiating 
into neuron-like cells (7, 8). Excessive glia and fibroblasts can 
increase glial scar formation (9). We theorized that BMSCs 
in vitro differentiation into more neuronal precursor cells than 
glia and fibroblasts before transplantation may represent a more 
effective therapeutic strategy. At present, several are methods 
used to induce the differentiation of MSCs into neural cells. 
These include exposure to cytokines, such as NGF, EGF, and 
bFGF (16); chemical induction with substances (17); exposure 
to brain homogenate (18); and gene transfection (19). Cytokines 
are commonly used as induction agents because they play a 
role in promoting stem cell proliferation and differentiation 
through their own receptors (20). We have demonstrated that 
hCSF-treated human BMSCs could successfully differentiate 
into neuron-like cells (10, 11). Three days of hCSF-induction 
prompts neurite growth, and the cultured cells gradually devel-
oped into a tapered, triangular, and irregular shape. The soma 
on day 7 was similar to the dendrite and axon-like structures of 
astrocytes. Compared with cytokine-induced cells, those that 
were induced with hCSF were quicker to differentiate and which 
also occurred in higher proportions (10, 11). This has resolved 
numerous problems associated with the use of culture media 
and stimulating factors.
The hCSF contains sufficient components to induce the dif-
ferentiation of MSCs into NSCs. hCSF provides a physiological 
microenvironment for the differentiation of MSCs into NSCs, 
which can not be substituted by artificial culture medium. The 
combination of hCSF and BMSCs presents a promise for clini-
cal application since both the hCSF and bone marrow could be 
obtained from patient himself without considering immune 
system. Since 2009, the Chinese government has been attempting 
to implement a clear policy for the clinical application of stem 
cells (http://www.stemcellsportal.com). We have demonstrated 
that hCSF-induced BMSC-Ns transplantation facilitates recovery 
in seven patients with nervous system diseases (21), suggesting 
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auto-BMSCs transplantation is a feasible, convenient, safe, and 
effective therapeutic approach. However, the survival, differ-
entiation, and integration with the organism of hCSF-induced 
BMSC-Ns in the brain of live animals after transplantation remain 
elusive. The total volume of adult rat CSF is approximately 580 μl, 
which limits the collection of a sufficient volume of rat CSF. In the 
present study, we used hCSF to induce rat BMSCs as transplanted 
cells. At day 4 post-induction by hCSF, cells were positive for both 
NSE and GFAP, but expression levels for NSE were higher than 
GFAP. This result is consistent with our previous results showing 
that induction of human BMSCs differentiation into neuron-like 
Cells with hCSF (10, 11).
The current mostly used transplantation ways in the treat-
ment of central nervous system diseases include target trans-
plantation, peripheral blood vessel injection (vein and artery), 
and cerebrospinal fluid transplantation (22–24). However, there 
is conflict in the choosing of transplantation ways, while which 
one is the best way remains unknown. Intravenous transplant is 
a way that in which NSCs are dropped into the blood circula-
tion system through venipuncture, by which stem cells reach 
the nervous system via blood circulation where stem cell shows 
its ability by penetrating blood–brain barrier. However, in 
addition to the long way to reach, long time to work, and the 
cells consumption, there are only 30% transplanted stem cells 
reach the central nervous system, while the rest are distributed 
in peripheral blood circulation. Transplantation through artery, 
which is associated with more cell conservation, however, is dif-
ficult to be utilized in clinical work. Ventricle puncture, through 
which transplanted stem cells could reach the ventricular 
system directly and then located the entire nervous system via 
circulation, which is also related to a higher transplant point, 
a shorter pass way, and a fewer loss of stem cell. Furthermore, 
transplantation through ventricle puncture may avoid volume 
mass effect and increase the number of transplanted cells, while 
brain environment provides a good place for migration develop-
ment and promote the directed differentiation of the implanted 
NSCs, in that the ventricle implanted cells could quickly reach 
the damage zone of the brain. Furthermore, cell transplantation 
can be achieved by lumbar puncture and intrathecal injection, 
this is in line with our reported clinical work (21). Studies have 
shown that within 24 hours after injury, most of the transplanted 
cells did not survive in the injured area and the lateral ventricles, 
this may be a result of from pathphysiological changes and 
secondary injury which are not conducive to the survival of 
transplanted cells. We transplanted stem cells 7 days after injury 
when the microenvironment was improved. Additionally, it 
would take 7 days to collect and induce the direct differentia-
tion of the autologous BMSCs. Stem cells have been reported to 
fail multi-lineage development when transplanted at ultra low 
density (3, 4), making assessment of dose-related integration 
into the niche an important variable. In this regard, while it has 
generally been assumed that “more is better,” in clinical trials, 
limited by small amount of autologous BMSCs, the number of 
stem cells was 0.54–2.8 × 108 (24). We chose 2 × 106 cells in rat 
in our experiment accordingly.
Our data revealed that hCSF-induced rat BMSC-Ns trans-
plantation in the lateral ventricles of MCAO rats significantly 
improved behavioral performances and cell differentiation as 
compared with BMSC group. We also found that BrdU+ cells 
were more than 80% when the cell confluence was over 90%. 
The BrdU+ cells can be observed even 32 days after transplan-
tation. The number of BrdU+ cells in the brain tissue after 
transplantation of hCSF-induced BMSC-Ns was significantly 
higher than that of hCSF-induced BMSCs. The numbers of both 
BrdU/GFAP-positive double-labeled and BrdU/NSE-positive 
double-labeled cells in the BMSC-N group were significantly 
higher than those in the BMSC group. However, the number of 
BrdU/NSE-positive double-labeled cells was greater than that 
of the BrdU/GFAP-positive double-labeled cells in the BMSC-N 
group and vice  versa. These results indicate that the BMSCs 
survived in vivo after transplantation tend to differentiate into 
astrocyte-like cells and that more neuron-like cells were found 
in the BMSC-N group than in the BMSC group. The in  vivo 
migration and differentiation of BMSCs in the present study 
were consistent with reports from other laboratories (25, 26). 
This result also supports our hypothesis that induction and 
differentiation of BMSCs toward specific target cells accord-
ing to clinical purposes before transplantation may be a more 
effective treatment strategy than transplanting BMSCs prior to 
differentiation.
In this study, we found that neurological function was 
 significantly improved 4 days after transplantation of eitherBM-
SCs or BMSC-Ns. This improvement could not be attributed to 
that necrotic cells were replaced by transplanted cells. Previous 
studies have demonstrated that the secretion, rather than sub-
stitution of local cells, during the early stage of implanted stem 
cell play the dominant role (7, 8, 27). The cells surrounding the 
early cerebral ischemic area are fragile and prone to apoptosis. 
Therefore, it is essential to protect the cells surrounding the 
damaged brain from being harmed by apoptosis. BMSCs and 
BMSC-Ns could enter the brain tissue and promote self-healing 
of neural tissue and improve neurological function through 
their own synthesis and secretion (28). They could also promote 
release of neurotrophic factor, vascular endothelial growth factor, 
nerve growth factor, and stem cell growth factor, which increase 
survival, migration, directed differentiation into neurons of 
endogenous NSCs, and injury repairmen (29, 30). The in vitro 
differentiation rate of BMSCs into neuron-like cells can be as 
high as 80%. However, in pathological condition, the in  vivo 
conversion rate of BMSCs is only 3–10% regardless of the 
methodology of transplantation into the cerebral ischemia area 
(31–33). After transplantation, the ratio of BMSCs differentiating 
into glial cells and fibroblasts is higher than the ratio of BMSCs 
differentiation into neuron-like cells in vivo. Excessive glia and 
fibroblasts potentiate the formation of glial scars, which restricts 
the growth of the axon in the damaged area or the recovery of 
neurological function. There is no doubt that glial scar formation 
impedes and negatively affects the recovery of nervous system 
function. Therefore, many researchers believe that it would be 
difficult to reconstruct neural pathways by completely replacing 
damaged nerve tissue using in  vivo differentiation of BMSCs. 
After transplantation in vivo in the present study, differentiation 
of hCSF-induced BMSC-Ns into neuron-like cells was signifi-
cantly higher, with less differentiation into glia-like cells than that 
8Ye et al. Cells for Treatment of MCAO
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of BMSCs. The early cellular secretion could support and provide 
nutrition to the local nerve tissues, and thus promote cell repair 
and functional recovery. However, in our research, neurological 
function significantly improved later. Our results indicate that 
the replacement of damaged or necrotic neurons by BMSC-Ns 
for reestablishment of neural pathways is a feasible therapeutic 
approach in the recovery of nervous system functions.
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